Article metrics

Download PDFPDF

Original research
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

 

Online download statistics by month:

Online download statistics by month: April 2023 to October 2024

AbstractFullPdf
Apr 202320520775
May 2023366367191
Jun 202325524784
Jul 202314013935
Aug 2023959235
Sep 2023756845
Oct 2023706736
Nov 2023796835
Dec 202311210733
Jan 2024676540
Feb 2024646241
Mar 2024595554
Apr 2024676440
May 2024706946
Jun 2024656043
Jul 2024635927
Aug 20244845162
Sep 20244946270
Oct 2024605687
Total200919431379